STOCK TITAN

Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Palatin Technologies, Inc. (NYSE American: PTN) will announce its Q4 and FY 2022 operating results on September 22, 2022, before U.S. market opens. A conference call will follow at 11:00 a.m. ET to discuss results and updates on development programs. Investors can access the audio webcast via Palatin's website. The company focuses on first-in-class biopharmaceuticals targeting melanocortin receptor systems, aiming for collaborations to enhance commercial potential. For updates, visit palatin.com.

Positive
  • Scheduled announcement of Q4 and FY 2022 results indicates transparency and accountability.
  • Focus on developing first-in-class medicines suggests potential for strong market position.
Negative
  • None.

CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 22, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast


Q4 & Fiscal Year End 2022 Results Press Release


9/22/2022 at 7:30 a.m. ET




Q4 & Fiscal Year End 2022 Conference Call-Live


9/22/2022 at 11:00 a.m. ET

     US/Canada Dial-In Number:


1-800-458-4121

     International Dial-In Number:


1-313-209-6672

     Conference ID:


8655999




Q4 & Fiscal Year End 2022 Conference Call-Replay


9/22/2022-9/29/2022

     US/Canada Dial-In Number:


1-888-203-1112

     International Dial-In Number:


1-719-457-0820

     Replay Passcode:


8655999




Audio Webcast Live and Replay Access


http://www.palatin.com

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-fourth-quarter-and-fiscal-year-end-2022-results-teleconference-and-webcast-to-be-held-on-september-22-2022-301627500.html

SOURCE Palatin Technologies, Inc.

FAQ

When will Palatin Technologies announce its Q4 and fiscal year end 2022 results?

Palatin Technologies will announce its Q4 and fiscal year end 2022 results on September 22, 2022, at 7:30 a.m. ET.

What time is the Palatin Technologies conference call scheduled for?

The conference call is scheduled for September 22, 2022, at 11:00 a.m. ET.

How can I access the audio webcast for Palatin's operating results?

You can access the audio webcast by visiting the 'Investors-Webcasts' section on Palatin's website at palatin.com.

What does Palatin Technologies focus on?

Palatin Technologies focuses on developing first-in-class biopharmaceuticals targeting melanocortin receptor systems.

Where can I find more information about Palatin Technologies?

More information about Palatin can be found on their website at palatin.com.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Latest News

PTN Stock Data

17.95M
18.86M
3.5%
7.88%
5.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CRANBURY